Diaconu C, Dogaru C, Coşman C, Livadariu R, Scarlat V, Miron L, Florea Irina, Bostaca Tamara
Universitatea de Medicină şi Farmacie Gr.T. Popa Iaşi Facultatea de Medicina, Clinica a III(-a) Chirurgie.
Rev Med Chir Soc Med Nat Iasi. 2010 Apr-Jun;114(2):428-33.
The aim of this study is to point out the late diagnosis and initiation of treatment in male with breast cancer. At the same time, to show the importance of the correlation between different markers in assessing the prognostic, as well as the treatment for the patient.
Retrospective study on a group of 15 males with breast cancer, out of 1043 patients with the disease, in a period of 10 years. Eight patients were stage III of disease, 2 were stage II, one was stage I, and in other 3 cases the evaluation of the tumor and of the axillary lymph nodes was performed only by echography, considered stage II.
All patients underwent radically modified Madden mastectomy; 4 patients needed a partial resection of the great pectoralis muscle. Adjuvant chemotherapy was performed in 9 patients, and neoadjuvant chemotherapy in 2 cases. Three patients refused the chemotherapy, and one patient chose an alternative paramedical treatment. The treatment with Tamoxifen was done in 11 patients with high values of Progesterone and Estrogen Receptors (PR, ER). At the date of our study, 8 patients were alive, without clinical signs of disease (free of disease), while in 3 patients, alive, clinical signs of disease were detected (recurrence). Survival rate couldn't be evaluated in 4 patients.
Breast cancer in male is usually discovered in locally advanced stages, although most of the patients are regularly screened for chronic hepatitis. Use of biological markers allows a more accurate evaluation of the aggressiveness of the tumor, as well as a more specific treatment for each patient. Modified radical mastectomy type Madden remains the preferred surgical approach. Surgical approach should be considered even in locally advanced cases, as well as in elder patients.
本研究的目的是指出男性乳腺癌的晚期诊断和治疗起始情况。同时,展示不同标志物之间的相关性在评估预后以及患者治疗方面的重要性。
对1043例乳腺癌患者中一组15例男性患者进行回顾性研究,研究时间为10年。8例患者为疾病Ⅲ期,2例为Ⅱ期,1例为Ⅰ期,另外3例仅通过超声检查评估肿瘤和腋窝淋巴结,被认为是Ⅱ期。
所有患者均接受了改良根治性马登乳房切除术;4例患者需要部分切除胸大肌。9例患者接受了辅助化疗,2例接受了新辅助化疗。3例患者拒绝化疗,1例患者选择了替代的辅助治疗。11例孕激素和雌激素受体(PR、ER)值高的患者接受了他莫昔芬治疗。在我们研究时,8例患者存活,无疾病临床体征(无病),而3例存活患者检测到疾病临床体征(复发)。4例患者的生存率无法评估。
男性乳腺癌通常在局部晚期被发现,尽管大多数患者定期接受慢性肝炎筛查。使用生物标志物可以更准确地评估肿瘤的侵袭性,并为每位患者提供更具针对性的治疗。改良根治性马登乳房切除术仍然是首选的手术方法。即使在局部晚期病例以及老年患者中也应考虑手术方法。